Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. - Wikidata - awgldk - TriplyDB

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

http://www.wikidata.org/entity/Q46424938

about

A Comprehensive Review of the Treatment of Atopic Eczema Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases Biological Treatments in Atopic Dermatitis New era of biologic therapeutics in atopic dermatitis Systemic therapy for atopic dermatitis Personalized Medicine in Allergy Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice Changing roles of eosinophils in health and disease.Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.Novel targeted therapies for eosinophil-associated diseases and allergy IgE-activated basophils regulate eosinophil tissue entry by modulating endothelial function Mepolizumab in eosinophilic disorders Biologic therapies targeting eosinophils: current status and future prospects.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.Anti-interleukin-5 antibody therapy in eosinophilic diseases.Mepolizumab.Management of itch in atopic dermatitis.A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers.Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases.Severe vitamin E deficiency modulates airway allergic inflammatory responses in the murine asthma model Therapeutic targets for new therapy for corticosteroid refractory asthma.Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.What's new in atopic eczema?Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.Update on the management of chronic eczema: new approaches and emerging treatment options Immune modulation for treatment of allergic disease.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.Clinical overview of cutaneous features in hypereosinophilic syndrome.Therapy of severe atopic dermatitis in adults.Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.Long term treatment concepts and proactive therapy for atopic eczema.Immunology of atopic eczema: overcoming the Th1/Th2 paradigm.Advances in the diagnosis and therapeutic management of atopic dermatitis.

P2860

Q26765975-B028D077-D095-4E89-B342-E4D1852E8780 Q26778683-19BD4807-6FEC-44E2-BF2D-70EB714E6EF1 Q26799579-F895FBB0-5624-4383-B9BD-BA26F12D8C7E Q27001941-9CAFC2EE-A92E-4D07-81A8-9E8A5B5B943C Q27005835-16E08899-6C00-42F5-B69D-EDFF81F82D52 Q28073074-ABA419D9-1742-463F-ACA0-EE1032EE4E59 Q28080207-2F05ABA4-8B52-4660-A60D-D1EA0956BE28 Q30543593-A963F66B-E5D6-4DDC-B62C-5E7433DE7C54 Q33713754-9C95DCA8-2E02-4651-B693-0F2237CEAA11 Q33780705-BA5DA071-189A-4E4E-A23C-57DF3C5363EE Q33787311-5A39E98B-037A-43C7-A524-EAC582F5A499 Q34441795-157CB70A-F47A-4C4E-AA7D-C951373C0B96 Q34444620-A8C58C7C-3B89-470B-A09B-9A76B00C845E Q35289192-70D4E8DB-A746-410D-BB26-5271292FDE80 Q35446671-C73574AE-065E-4AA6-A955-86C7DB46A45C Q35565533-C3E28D13-A590-463D-A626-2EE9E53B8A37 Q36214254-E34CF0F2-6723-45D5-B137-906097670639 Q36437966-E5D034F6-A052-4C34-A2C9-660ECF4F4068 Q36438486-15AC476C-B76C-4E2A-BB96-8E36A0B2DE02 Q36977252-555A56F9-060A-46F4-8E88-00F224B1CA1D Q36991444-C717DA73-7076-44C0-83C7-4E6E3B328AD0 Q37031192-F2A0AD46-DABF-4830-826F-CCC48AC376BF Q37059851-667DEEAD-BAC5-4D55-AF19-2063D82A120A Q37185022-4E57F44B-3803-4D8F-AE07-9E288204B929 Q37336072-821B5C44-9B3E-42C1-AECB-A0081EB29D14 Q37404698-55A02562-5C18-4EEF-922E-1BE1370EA888 Q37573811-F1E52E65-27C4-408D-A4D4-EFF73E831D3A Q37731037-C9D7D6EB-0AA4-44E5-A5C1-6AA7162B7D06 Q37740142-CD615462-E695-4682-ABAC-1D460673282F Q37755233-860F9739-1D5C-403A-A00B-435F3679DF07 Q37846670-3E1A6A54-E338-4918-B792-89FFE3FD7ED3 Q37857682-1C75A104-6115-4721-A4AE-F64E55E2A495 Q37891140-39DBDF98-C2D8-45FA-9B18-121B072ED28C Q37957225-2EBBFC1F-B51B-4B71-8FA2-2EAC3208BBC2 Q37987470-C7B88A5C-C65F-4661-AB55-9A334742E264 Q38011193-2CFFFB48-319C-45D9-A4BE-731474C2C3EB Q38027604-DB2EAF94-9866-45DC-9A9E-7831577C977D Q38033549-8E1727A5-D3BC-4077-BED2-73C6E5CCCADD Q38124385-1C58E1D5-D5A5-454C-BF81-2404207D45E5 Q38211352-BF908ADC-CC4C-4222-8996-99455EFFD427

P2860

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

http://www.wikidata.org/entity/Q46424938

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.

@en

Anti-IL-5 recombinant humanized monoclonal antibody

@nl

type

label

Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.

@en

Anti-IL-5 recombinant humanized monoclonal antibody

@nl

prefLabel

Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.

@en

Anti-IL-5 recombinant humanized monoclonal antibody

@nl

P1433

Q46424938-62C917A8-1F32-41B4-A037-B7280E78F9D8

P1476

Q46424938-0147F0B2-E63C-44FA-87C8-E475DA3AC752

P2093

Q46424938-2A82E12D-A19A-43AA-B743-0CDC1376A633

Q46424938-342AC7A7-9D90-4A1D-B821-DA481CCDE97A

Q46424938-63D704BB-7173-40B4-BC33-E12855D46EDC

Q46424938-6F5736AB-C833-42F5-8207-7ABACDE3FE87

Q46424938-9FC0C09B-F259-4998-AB43-4512A15EE40B

Q46424938-CCE46506-0C72-4D0C-B728-C2FBCC23E1BF

Q46424938-E5921C0E-8084-4338-9689-647FE6311F9D

Q46424938-E5F3D7A0-E72F-44E7-A67E-8DADBD450D36

Q46424938-F1D6A0A7-E588-4B3A-951A-167A2AB6C8B5

Q46424938-F6582247-2112-4EA0-8974-4FD9D61F53E9

P2860

Q46424938-599AA770-A3D5-4301-86C8-0D03F440B071

Q46424938-5EFB9352-33DF-4C1A-85A1-6B06B1EE8901

Q46424938-674565F4-1DC6-4A96-819E-C4EF3C4961B5

Q46424938-8A4C2E5F-F930-4512-8C20-6080A0771FF1

Q46424938-8A4F2BC5-E037-41C0-AED6-885CE34C4191

Q46424938-9084E669-198A-48E3-8B83-FB20EBDF4BFC

Q46424938-C0914303-7FE1-42CA-B740-D95381553EA8

Q46424938-F5CB9605-2D23-4736-B703-9D37801DB770

P304

Q46424938-AFE63C38-9B3A-48C6-88EC-1A7512A7EE51

P31

Q46424938-CA9A9830-E579-4863-B89E-410297ADB326

P356

Q46424938-A0C0BB88-74F9-4DAC-8096-D69F8083A54D

P433

Q46424938-736F83ED-8439-4C20-9889-F0936C6EFC98

P478

Q46424938-F857BDD2-36D4-465D-AC61-130991D54C6D

P50

Q46424938-02B56A8D-6DC5-446A-A8BE-6E9ED4821FEB

Q46424938-166E4AB1-4640-4E3A-BF97-51BBFA0D1A6C

P577

Q46424938-AEF775D7-BBA0-461A-B892-1F4E74ACAAFE

P5875

Q46424938-6B85DEDE-C7B5-461B-B175-EEF1DA182143

P698

Q46424938-7B05B320-9B5A-4D30-8B21-25AD115F9FEC

P921

Q46424938-5D06D72C-148E-4C50-A0BD-809FD11289D1

Q46424938-7E7EA8DC-F32F-4BCA-B8EC-FA5EDF11B3CB

P356

J.1398-9995.2005.00791.X

P1433

P1476

Anti-IL-5 recombinant humanize ...... treatment of atopic dermatitis

@en

P2093

Bruijnzeel-Koomen CA

http://www.w3.org/2001/XMLSchema#string

Darsow U

http://www.w3.org/2001/XMLSchema#string

Kapp A

http://www.w3.org/2001/XMLSchema#string

Katzer K

http://www.w3.org/2001/XMLSchema#string

Laifaoui J

http://www.w3.org/2001/XMLSchema#string

Oldhoff JM

http://www.w3.org/2001/XMLSchema#string

Plötz S

http://www.w3.org/2001/XMLSchema#string

Ring J

http://www.w3.org/2001/XMLSchema#string

Werfel T

http://www.w3.org/2001/XMLSchema#string

Wulf A

http://www.w3.org/2001/XMLSchema#string

P2860

Development of IL-5 receptor antagonists.

Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.

Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions.

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

P304

693-696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1398-9995.2005.00791.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Edward Frank Knol

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7922267

http://www.w3.org/2001/XMLSchema#string

P698

15813818

http://www.w3.org/2001/XMLSchema#string

P921